← SynDRA
VOXTALISIB
SynDRA canonical compound SYN0038286 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Primary target(s) | PIK3CA |
|---|
| Mechanism of action | PI3K inhibitor |
|---|
All known targets
- MTOR
- PIK3CA
- PIK3CG
- PIK3CB
- PIK3CD
- PIK3R1
- PIK3R2
- PIK3R3
- PIK3R5
Mechanisms of action (all sources)
- MTOR inhibitor
- PI3K inhibitor
- Serine/threonine-protein kinase mTOR inhibitor
- PIK3R1 INHIBITOR
- PIK3CB INHIBITOR
- PIK3CG INHIBITOR
- PIK3CA INHIBITOR
- PIK3R2 INHIBITOR
- PIK3CD INHIBITOR
- PIK3R5 INHIBITOR
- PIK3R3 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PIK3CB
- SYK
- PIK3CD
- PDGFRB
- PHKG2
- PGRMC1
- PFKP
- PEBP1
- PDXK
- AAK1
- PAK2
- PAICS
- OPA1
- OLA1
- NUAK2
- NTRK1
- PAK4
- PIM1
- NLK
- PRKACA
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACG
- PRKACB
- PRKAA1
- PIP4K2A
- PLK4
- PLK1
- PKN2
- PKN1
- PKMYT1
- PIP4K2C
- NQO2
- NEK9
- PRKCD
- MAPK15
- MAPKAPK5
- MAPKAPK2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2C9
- GPX1
- GPX4
- IFNG
- KSYK
- NSD2
- NTM1A
- NTMT1
Cross-references
Synonyms
- SAR-245409
- SAR245409
- XL-765
- XL765
- 2-amino-8-ethyl-4-methyl-6-(1h-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7(8h)-one
- Voxtalisib (XL765, SAR245409)
- CVL1685GPH
- 2-amino-8-ethyl-4-methyl-6-(1h-pyrazol-3-yl)pyrido[2,3-d]pyrimidin-7(8h)-one
- Pyrido(2,3-d)pyrimidin-7(8H)-one, 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-3-yl)-
- UNII-CVL1685GPH
- Voxtalisib [USAN:INN]
- 2-AMINO-8-ETHYL-4-METHYL-6-(1H-PYRAZOL-5-YL)PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE
- VOXTALISIB [INN]
- Voxtalisib (USAN/INN)
- Voxtalisib (XL-765)
- VOXTALISIB [USAN]
- 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)pyrido[2,3-d]pyrimidin-7-one
- VOXTALISIB [WHO-DD]
- SCHEMBL189573
- CHEMBL3545366
- CHEBI:124914
- DTXSID701025755
- BCP16243
- EX-A4140
- BDBM50519385
- NSC791226
- NSC800972
- s7646
- ZINC35308805
- AKOS037515701
- CCG-267162
- CS-3163
- DB12400
- NSC-791226
- NSC-800972
- SAR 245409
- SB16573
- NCGC00387875-03
Look up VOXTALISIB in the interactive SynDRA portal →